For instance, MSCs genetically modified with anti-CD33−CD3 bifunctional antibodies genes may revoke the onset of AML in nonobese diabetic/severe combined immunodeficiency IL2Rγ−/− (NSG) mice and redirect allogeneic T-cells against AML patient-derived blasts [194,195]. This evidence concerns the gene IL2RG and acute myeloid leukemia.